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Background and purpose: The screening tool for diagnosing lower extremity arterial
disease is the assessment of the ankle-brachial index (ABI), which is widely used in general
practice. However, resting ABI can easily produce a false negative result. In light of this, our
goal was to determine the proportion of deﬁnitive diagnoses (peripheral arterial disease
[PAD] conﬁrmed or refuted) among patients screened in general practice, and the rate of
cases in which the need for further specialized examination is necessary, with special
attention to groups having non-compressible arteries and ABI negative symptomatic status.
The aim of our work is to improve the efﬁciency of primary health care screening in PAD
and reduce the extremely high domestic amputation ratio.
Patients and methods: Eight hundred and sixteen patients were screened. We used the
Edinburgh Questionnaire and recorded medical histories, major risk factors, current com-
plaints, and medication. Physical examinations were performed, including ABI testing.
Results: Thirty-three percent complained about lower extremity claudication; 23% had
abnormal ABI values; 13% of the patients within the normal ABI range had complaints of
dysbasia; and 12% were in the non-compressible artery group. The ABI-negative sympto-
matic group’s risk factor proﬁle showed a close similarity to the clear PAD-positive and non-
compressible artery groups.
Conclusion: The percentage of PAD could be higher than the number of patients diagnosed
by ABI screening. Nearly a quarter of the population fell into the non-compressible artery
and ABI-negative symptomatic groups, together deﬁned as the “murky zone”. When screen-
ing purposely for PAD, these patients deserve special attention due to the insufﬁcient
selectivity and sensitivity of measurements. If there is high clinical suspicion of PAD in
spite of normal ABI values, further assessment may be considered.
Keywords: peripheral arterial disease, ankle-brachial index, diabetes, screening method,
ABI-negative symptomatic, non-compressible artery
Introduction
Cardiovascular diseases (CVDs) are a leading cause of death in Europe.
Early recognition of lower extremity peripheral arterial disease (PAD) is of
crucial importance, as patients with vascular diseases are at 2–4 times the risk of a
future cardiovascular or cerebrovascular event.1–3 Early recognition and adequate
treatment signiﬁcantly decrease associated risks and mortality.4
Lower extremity PAD is a common disease. Among the age 55+ demographic,
its prevalence increases exponentially; for ages 65 and above, prevalence can be as
high as 20%.1,6 The majority of patients is asymptomatic, and remains undiscov-
ered without special screening.1,4
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The largest Hungarian epidemiological study in this
ﬁeld was the ÉRV Programme which estimated the pre-
valence of lower limb PAD to be at 14.4% among hyper-
tensive patients.7
The most important risk factors of lower extremity
PAD are: smoking, diabetes mellitus, dyslipidemia, hyper-
tension, and aging.4
In Hungary, major amputations are estimated at triple
the international average, one of the causes being the late
recognition of lower limb PAD.8
The dual purpose of our study was to measure the
prevalence and severity of lower extremity PAD and to
develop a low-cost, complex screening method for general
practitioners (GPs) that is easy to perform, requires few
instruments, and may quickly yet accurately identify both
PAD patients and at-risk patients, thus promoting early
disease recognition. We decided to deﬁne the characteris-
tics of two speciﬁc groups particularly difﬁcult to diagnose
at GP level. One such group is where the ankle-brachial
index (ABI) shows normal or borderline values, but the
Edinburgh Questionnaire (ECQ) clearly suggests lower
limb PAD (we refer to this group as “ABI-negative symp-
tomatic”); the second group consists of those who suffer
from identiﬁable atherosclerosis, but the hardening of their
arterial walls results in false high ABI values, making
evaluation impossible. This population is referred to as
the “non-compressible artery group”.
Participants and methods
Our study took place between November 2015 and April
2017, with 816 participants from 33 GP practices. The
participation of GPs was voluntary.
We advertised the screening one month prior to the
examination at GP ofﬁces, randomly chosen from the
capital, major cities, and small villages.9 The target demo-
graphic included men and women aged 50+. We screened
every patient aged 50–65 with at least one major vascular
risk factor or CVevents in their personal or family medical
history, as well as everyone aged 65 and above. All parti-
cipants received a written informed consent before invol-
vement in the study. Everyone signed and agreed the
participants’ consent, which was performed according to
the Helsinki Declaration. Our study has been approved by
all the authors and the Research Ethics Committee of the
Semmelweis University (285/2015).
We began the examination by completing the
Edinburgh Claudication Questionnaire (ECQ), a validated
and frequently used method of screening for intermittent
claudication (IC).10
We recorded the patient’s medical history, any CVevents
in their family’s medical history, any currently prescribed
medications, as well as the details of major risk factors
(smoking, diabetes, hypertension, or hyperlipidemia).
Figure 1 shows us the screening method and algorithm
that we used.
Basic body measurements (height, weight) as well as
serum glucose and cholesterol-level measurements with
test strips were performed. After a 5-mins rest, we mea-
sured blood pressure and pulse rate on both upper extre-
mities (blood pressure manometer, Bosch Konstante). In
accordance with current guidelines, a continuous wave
Doppler-US instrument (8 MHz; MultiDOPPY) was used
to measure systolic blood pressure in all four extremities,
and ankle-branchial index (ABI) was calculated from the
pressure values.1,11
We performed a walking test for patients whose ECQ
revealed IC complaints. They had to walk along a pre-
cisely measured course at normal walking pace, while we
registered various data. We recorded if the pain occurred
before or after walking 200 meters. These data were used
for Fontaine-stage classiﬁcation. Patients walked for 6
mins at most (for calculating a 6-mins walking distance).
Screening
Medical history
Family Own
Disease
Medication
Risk factors
Walking-test
Edinburgh questionnaire Examination
Physical ABI Blood test
Figure 1 Screening procedure algorithm.
Abbreviation: ABI, ankle-brachial index.
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We determined pain-free walking distance (the distance at
which lower limb pain ﬁrst occurred) as well as maximum
walking distance (the distance at which the pain forced the
patient to stop).
In patients with lower extremity symptoms, additional
examinations were performed to differentiate the origin of
the pain.
Mean values and percentages were calculated in cases of
continuous and categorical variables, respectively. Group
differences were compared using the Fisher’s exact test for
categorical variables, two-samples t-test (where the homoge-
neity of variances and the similar sample sizes made it pos-
sible), and unequal variances t-test for continuous variables.
Results
Total population data
The screened population’s baseline parameters are shown
in Table 1. More than half (62%) of the participants at our
screenings were women. Patients were mainly from the
elderly age group, average age being 65.6±7.9 years. The
most frequent vascular risk factor was hypertension at
77%, followed by hyperlipidemia (55%), diabetes (33%),
and active smoking (24%). Based on the ECQ, a
signiﬁcant percentage (33%) of the total population had
IC complaints.
Patients with negative at-rest ABI results and no symp-
toms indicating sclerosis were classiﬁed as clear PAD-
negative. Patients with normal at-rest ABI results but
whose ECQ results revealed symptoms of IC were classi-
ﬁed as ABI-negative symptomatic.
The clear PAD-positive group comprises patients
whose ABI results were positive, and clearly suffer from
atherosclerosis, the asymptomatic or symptomatic stenosis
or occlusion reducing blood ﬂow. Patients whose major
arteries are hardened (such as hardening caused by medial
sclerosis) have non-compressible arteries. Due to this,
blood pressure values at the ankle often show false high
values, and the ABI is over 1.4. This category is referred
to as the non-compressible artery group.
We named the clear PAD-positive and the clear PAD-
negative groups the “light zone”, because, using our
screening method, these patients can be diagnosed with
great conﬁdence by primary care practitioners. On the
other hand, the ABI-negative symptomatic and the non-
compressible artery groups are called the “murky zone”,
referring to the diagnostic difﬁculties of these groups
(Table 2).
Tables 3 and 4 show the results of the risk factor
distribution and differences between the observed groups
of patients, Table 5 shows the distribution of clear PAD
patients according to the Fontaine classiﬁcation, while
Table 6 shows the results of the walking test.
Clear PAD-negative group
Fifty-two percent of the population were categorized into
the negative at-rest ABI group. Average age was the low-
est here, 64.7±7.8 years. In this group, the most frequent
risk factor was hypertension (72%), followed by hyperli-
pidemia (50%), and diabetes (28%). The number of active
smokers was also the lowest here (15%).
Clear PAD-positive group
Based on at-rest ABI values, 23% of the examined patients
could be clearly categorized as suffering from athero-
sclerosis. Of these, 57% were men. The mean age was
66.6±7.7 years. The most frequent risk factor was hyper-
tension at 87%, followed by hyperlipidemia at 68%. The
numbers of both active (45%) and former (29%) smokers
were the highest here. The percentage of diabetes patients
was 36%. A signiﬁcant number of patients had a medical
history of stroke (9%) and infarction (11%). The
Table 1 Baseline parameters
Full population (n=816)
Average age (y±SD)
Females, n (%) 505 (62)
Active smoker, n (%) 197 (24)
Former smoker, n (%) 210 (26)
Hypertension, n (%) 634 (77)
Diabetes, n (%) 260 (32)
Hyperlipidemia, n (%) 449 (55)
Prior stroke, n (%) 53 (6)
Prior MI, n (%) 71 (9)
Diagnosis for PAD, n (%) 106 (13)
Obesity, n (%) 661 (81)
Alcohol abuser, n (%) 19 (2)
Claudication positive (all), n (%) 272 (33)
Claudication positive (women), n (%) 151 (19)
Medication
Antihypertensive, n (%) 589 (72)
Lipid-lowering, n (%) 226 (28)
Antidiabetic, n (%) 188 (23)
Antiplatelet, n (%) 228 (28)
PAD speciﬁc, n (%) 92 (11)
Diuretics, n (%) 48 (6)
Abbreviations: MI, myocardial infarction; PAD, peripheral arterial disease.
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percentage of claudicating patients was the highest, at
74%. The most frequently prescribed medications were
antihypertensives (79%) and antiplatelets (38%). PAD-
speciﬁc medication had been previously prescribed to
22%. The majority of patients in this group were in
Stage IIb of the Fontaine classiﬁcation (49%).
ABI-negative symptomatic group
Thirteen percent of the total population were categorized
into this subgroup. The most frequent risk factor was
hypertension (81%). This subgroup has the second highest
percentage of active smokers (28%). Medical histories
most frequently revealed associated diseases, including
stroke (13%) and myocardial infarction (23%). These
patients were most commonly diagnosed with PAD
(32%). Patients were most commonly prescribed antihy-
pertensives (83%), while 31% received PAD-speciﬁc
medication.
Non-compressible artery group
This group comprised 12% of the examined population.
Average age was the highest at 67.3±8.5 years. The most
frequent risk factors were again hypertension (81%), fol-
lowed by hyperlipidemia (49%). The percentage of dia-
betes patients was the highest here (37%). This group had
the highest percentage of obese patients (87%). A signiﬁ-
cant 28% of the patients had IC complaints. Of this, 65%
were women. The most frequently prescribed medications
were antihypertensives (73%).
Discussion
Lower extremity PAD is often diagnosed late in GP prac-
tices. Current recommendations suggest the use of non-
invasive ABI measurement for screening. Its sensitivity
and speciﬁcity for lower extremity PAD can be estimated
between 79% and 96%.10 It may indicate abnormalities
even before the patient develops complaints of
dysbasia.12,13
In our screenings, we have made the same important
observation similar studies had also faced: in spite of
having adequate equipment and trained personnel, the
regular performance of ABI measurements is not guaran-
teed if the importance and associated risks of PAD remain
unknown.14,15
Based on ABI measurements, our study categorized
nearly a quarter of all examined patients into the clear
PAD-positive group. This result matches the data of simi-
lar studies.1,5–8,12 It is important that a quarter of these
patients were asymptomatic, as the lack of complaints
further hinders the recognition of PAD by the GP. The
average age within this group was almost 1 year above the
average age of the total population, which indicates the
importance of age as an independent risk factor. Although
a higher number of women participated in the screening,
both the number and percentage of PAD were almost one
and a half times higher among men. This correlates with
literature data.1,4,16
We have found a signiﬁcant presence of risk factors, and
in most cases, the co-occurrence of multiple risk factors.
Smoking is a particularly important risk factor. It
increases the risk of occurrence by 2–6 times, and this
increases with the amount and years of smoking.2,17,18
Smoking has a closer connection with lower extremity PAD
than with coronary diseases.17 The percentage of active
smokers was highest in the clear PAD-positive group – one
and a half times the Hungarian average.19 The percentage of
former smokers was also the highest, as opposed to the clear
PAD-negative group, where it was at half the Hungarian
average. Quitting smoking rapidly decreases the occurrence
of IC complaints.20
Diabetes mellitus patients are at 2.4 times the risk of
PAD, and also face a higher risk of developing critical
Table 2 Distribution of patients according to ABI results and symptoms
Selection Light zone Murky zone
Groups Clear PAD-negative Clear PAD-positive ABI-negative symptomatic Non-compressible artery
ABI 0.9–1.4 <0.9 0.9–1.4 >1.4
Symptoms Negative Neg. or pos. Positive Neg. or pos.
n (%) 425 (52%) 185 (23%) 109 (13%) 97 (12%)
Men 137 (32%) 105 (57%) 37 (34%) 31 (32%)
Women 288 (68%) 80 (43%) 72 (66%) 66 (68%)
Mean age 64.7±7.8 66.6±7.7 66.3±8.1 67.3±8.5
Abbreviations: ABI, ankle-brachial index; PAD, peripheral arterial disease.
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limb ischemia (CLI).21 The risk of future amputation is
ﬁve times higher for them, and this risk increases with the
number of years they suffer from diabetes.22
Approximately, one-third of the examined population was
diabetic. The percentage of DM was the highest in the
non-compressible artery group, followed closely by the
clear PAD-positive and the ABI-negative symptomatic
groups. It is important that among the patients of the
non-compressible artery and ABI-negative symptomatic
groups, it is most frequently impossible to accurately
screen for PAD in primary health care using the means
available to GPs.
Hypertension is one of the most signiﬁcant risk factors,
although its connection to PAD is weaker than to coronary
diseases.23,24 Three quarters of the examined patients had
hypertension, which was also the most common risk factor
across all examined groups. Its occurrence was highest in
the clear PAD-positive group and lowest in the clear
PAD-negative group.
Atherosclerosis has a close connection to low HDL and
high LDL and triglyceride levels.4,25–27 In the examined
population, the prevalence of dyslipidemia was 55%. The
highest percentage was in the clearPAD-positive group,
and a similarly high prevalence can be seen in the
ABI-negative symptomatic group.
The occurrence of stroke in the medical history of
either parent triples the risk of a similar event for the
descendants.28 Some studies suggest that early-developing
CVDs are much more common among individuals whose
parents suffered in PAD, and the tendency to develop IC
is, in all likelihood, hereditary.29,30 We found the highest
percentage of stroke and AMI among the ﬁrst degree
relatives of the ABI-negative symptomatic group.
The ABI-negative symptomatic group comprises
patients whose at-rest ABI values were normal or border-
line, but show symptoms of IC based on the ECQ. Such
situations reveal that at-rest ABI measurement in itself is
often insufﬁcient for accurate diagnosis. If the patient’s at-
rest ABI measurement results are normal or borderline, but
the patient has complaints, a further exercise test is needed
Table 4 Risk factor, comorbidity, and medication differences between clear PAD-positive and ABI-negative symptomatic groups
Groups Clear PAD-positive (n=185) ABI-negative symptomatic (n=109) F exact p-value 0.05
Ratio in the group, n (%) Ratio in the group, n (%)
Active smoker 83 (45) 31 (28) 0.006
Former smoker 53 (29) 26 (24) 0.415
Hypertension 161 (87) 88 (81) 0.179
Diabetes 66 (36) 38 (35) 0.901
Hyperlipidemia 126 (68) 65 (60) 0.164
Prior stroke 16 (9) 14 (13) 0.318
Prior MI 21 (11) 25 (23) 0.012
Diagnosis for PAD 40 (22) 35 (32) 0.052
Obesity 138 (75) 85 (78) 0.573
Alcohol abuser 3 (2) 0 (0) 0.297
Claudication positive (all) 136 (74) 109 (100) <0.0001
Medication
Antihypertensive 146 (79) 91 (83) 0.363
Lipid-lowering 57 (31) 42 (39) 0.201
Antidiabetic 53 (29) 32 (29) 0.894
Antiplatelet 71 (38) 46 (42) 0.539
PAD speciﬁc 40 (22) 34 (31) 0.072
Diuretics 5 (3) 15 (14) 0.001
Abbreviations: ABI, ankle-brachial index; PAD, peripheral arterial disease; MI, myocardial infarction.
Table 5 The distribution of PAD-positive patients according to
the fontaine classiﬁcation
Fontaine classiﬁcation n=185
I 48 (26%)
IIa 43 (23%)
IIb 90 (49%)
III 1 (0.5%)
IV 3 (1.5%)
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(Treadmill test, Strandness protocol: 3 km/hr, 10% slope).
In our cohort, one-ﬁfth of normal or borderline ABI value
patients had lower limb complaints connected to walking.
If systolic pressure falls by more than 30 Hgmm at the
ankle by the end of the Treadmill test (reaching maximum
walk distance), or if ABI decrease is more than 20% after
exercise, a diagnosis of PAD can be established.1 We
found the second highest number of active smokers
among ABI-negative symptomatic patients. The same is
true for hypertension and hyperlipidemia. This group
showed the highest incidence for stroke, myocardial
infarction, all other heart diseases, and patients in this
group most frequently had a previous diagnosis of athero-
sclerosis and PAD. These results show the importance of
not relying solely on at-rest ABI values for establishing a
diagnosis of lower limb PAD. Instead, it is highly recom-
mended to take a multi-directional approach even at GP
level.
The non-compressible artery group also requires spe-
cial attention. This group comprises over one-tenth of the
examined population, and has the highest average age and
the most frequent occurrence of DM. Besides physical
examination (such as the palpation of peripheral blood
vessels), it is recommended to perform both the ECQ
and a walk test, in order to determine whether the patient
has complaints of dysbasia. Guidelines advise the use of
TBI, which can be performed by angiology specialists. If
the TBI value is below 0.7, the patient is diagnosed with
lower limb PAD.1,4
Between the clear PAD-positive and clear PAD-negative
groups, we found statistically signiﬁcant differences in the
following cases: active smoking, hypertension, hyperlipide-
mia, obesity, prior myocardial infarction, and prior
PAD diagnosis. Differences were also signiﬁcant regarding
antihypertensives, antidiabetics, antiplatelets, and
PAD-speciﬁc medicines. Analysis of the clear PAD-nega-
tive and ABI-negative symptomatic groups yielded the
following results: active smoking, prior stroke, MI and
PAD diagnosis, furthermore each medication except diure-
tics. The non-compressible artery group and the ABI-nega-
tive symptomatic group differed only in the “prior
PAD diagnosis” and “PAD-speciﬁc medication” factors.
The difference between the clear PAD-positive and
ABI-negative symptomatic groups was signiﬁcant only in
the active smoking, prior MI, claudication, and diuretics
categories.
The lowest average pain-free walking distance was
measured among the patients of the ABI-negative sympto-
matic group (the subgroup in which pain was reported
during the assessment). Additionally, the same group pro-
duced the lowest average maximal walking distance. The
clear PAD-positive and ABI-negative symptomatic groups
showed signiﬁcant difference in both pain-free walking
distance and maximum walking distance; and so did the
ABI-negative symptomatic and non-compressible artery
groups. The difference between the clear PAD-positive
and non-compressible artery groups was not signiﬁcant.
On Figure 2 is our proposed screening algorithm for
GPs. The whole process takes 15–20 mins, requires little
equipment, and considerably improves the quality of life
and life expectancy of screened patients potentially at risk.
Furthermore, the long-term beneﬁt of screening for lower
extremity PAD in GP is the diagnosis of the disease in an
early stage, thus allowing for an earlier commencing of
treatment, leading to a decrease in future health care costs.
Conclusions
The role of the GP is particularly important in the preven-
tion and early recognition of PAD. The complex approach
of our method enables the practitioner to identify at-risk
patients who belong to the murky zone. These patients
would remain invisible to doctors using instrumental mea-
surements only, and require further examinations from a
differential diagnostic perspective. On the long run,
Table 6 Differences in average walking distances in the observed groups of symptomatic patients during walking test compared to the
clear PAD-positive patients
Walking
distances (m)
A, Clear PAD-
positive (n=136)
p-value
0.05 (AB)
B, ABI-negative
symptomatic (n=34)
p-value
0.05 (AC)
C, Non-compressible
artery (n=27)
p-value
0.05 (BC)
Pain-free
walking distance
191.9±111.9 <0.001 115.7±63.3 0.616 207.8±106.2 0.002
Maximum
walking distance
269.2±116.6 <0.001 170.4±80.8 0.637 267.8±112.8 0.017
Abbreviations: ABI, ankle-brachial index; PAD, peripheral arterial disease.
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launching a complex screening program at GP level makes
PAD patients easier to diagnose, which would lead to an
earlier start of treatment, signiﬁcantly improving both the
patients’ quality of life and life expectancy.
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